Follow-up of patients with R/R FLT3-mutation–positive AML treated with gilteritinib in the phase 3 ADMIRAL trial

Key Points Long-term gilteritinib therapy sustained remission, leading to better long-term survival than chemotherapy in relapsed/refractory FLT3+ AML. The safety profile of gilteritinib was stable over a 2-year period, with no new or clinically significant safety signals.